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Introduction
Aromatase inhibitors (AI) are a novel adjuvant endocrine
treatment for estrogen receptor (ER)-positive, postmeno-
pausal breast cancer. They function by inhibiting the aro-
matase enzyme that converts androgens into estrogens.
AIs have demonstrated excellent efficacy in clinical trials
and have shown supremacy over Tamoxifen. However,
prolonged use of AIs can lead to acquired resistance. This
resistance is characterised by aberrant ER signalling and
crosstalk with growth factor pathways. CyclinD1 is cur-
rently being investigated in the lab in an AI resistant
breast cancer cell line (Let-R) and there is evidence of dif-
ferential gene expression when compared to classical
genes such as pS2. In Let-R cells, cyclinD1 expression
appears to remain estrogen regulated. It is thought that
this is not solely regulated through ER but through estro-
gen signalling to c-jun N-terminal kinase (JNK). This
study aims to characterise the Let-R cell line created in
the lab and to optimise an ERa knockdown in Let-R cells.
Methods
Parental MCF-7, aromatase-overexpressing (Aro) and
Let-R cell lines were used to investigate protein expression
levels of ERa, cyclinD1, JNK and c-jun using Western
blots. Cells were transfected with ERa SiRNA to optimise
the knockdown in Let-R cells.
Results
Let-R cells have higher levels of ERa compared to Aros.
CyclinD1 basal levels are elevated in Aro cells compared
to Let-Rs. Levels of JNK and c-jun are higher in Let-R
cells compared to Aros. A highly effective ERa knockdown
in Let-R cells was optimized.
Conclusions
The significant ERa knockdown achieved in the Let-R
cells will enable further examination of knockdown
effects on protein levels and mRNA expression. Elevated
expression of ERa in the Let-R cells observed is consis-
tent with the association between AI resistance and ER
hypersensitivity. In resistant cells, the decrease in basal
levels of CyclinD1 may be partly responsible for the lack
of regulation of classical genes like pS2, previously
detected by the lab. The elevated levels of JNK and c-jun
observed in Let-R cells supports the theory of crosstalk
between the ER and growth factor pathways in resistance.
Furthermore, it would be of interest to accompany AI
treatments with growth factor inhibitors to further our
understanding of endocrine resistance.
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